Original articleIntravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Section snippets
Methods
The study procedures have been reported1 and are summarized briefly. The study adhered to the tenets of the Declaration of Helsinki. The protocol and Health Insurance Portability and Accountability Act–compliant informed consent forms (the original study consent and extension study consent) were approved by institutional review boards. The protocol is available on the DRCR.net website (www.drcr.net; accessed June 13, 2014). In brief, participants had at least 1 eye with visual acuity
Results
After excluding deaths, the 5-year completion rate was 76% of the 163 original participants randomized to the ranibizumab + prompt laser group and 74% of the 150 original participants randomized to the ranibizumab + deferred laser group. Because the fourth and fifth years were extensions of the original study, some patients chose not to consent to the longer follow-up. Among those consenting and surviving through 5 years, the completion rate was ranibizumab plus prompt laser (97%) and
Discussion
When the DRCR.net reported the 1-year study results demonstrating an improvement in mean visual acuity in eyes with vision loss from DME involving the foveal center that had been treated with ranibizumab, the question of whether this improvement could be safely sustained over time and, if so, how many treatments were given within the DRCR.net protocol remained. Furthermore, the 1-year results did not suggest that prompt laser treatment added value when initiating ranibizumab compared with
References (6)
- et al.
The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
Ophthalmology
(2011) - et al.
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
Ophthalmology
(2010) - et al.
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
Ophthalmology
(2011)
Cited by (0)
Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): M.J.E.: grants − iCo Therapeutics, Jaeb Center; Consultant – Genentech; Payment for lecture including service on speaker's bureau – The Scienomics Group Bryn Mawr Communication.
N.M.B.: principal investigator − grants at The Johns Hopkins University sponsored by Bayer, Genentech, Inc., Novartis Pharma AG, Regeneron, and The Emmes Corporation through the Office of Research Administration of the Johns Hopkins University School of Medicine, and has a contract agreement from the American Medical Association to the Johns Hopkins University School of Medicine.
D.B.: royalties − Springer; grants − Aerpio, DRCR Network, Jaeb Center for Health Research, Inc., Novartis, and Regeneron; has provided expert testimony for Novartis; Consultant − Springer Inc., Alimera, and Novartis.
T.W.S.: grants − Eli Lilly, Emmes, Genentech, and Regeneron; Besse Medical.
Supported through cooperative agreements from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services (grant nos. EY14231, EY14229, EY18817, EY023207). The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation of the manuscript. Genentech provided the ranibizumab for the study and funds to DRCR.net to defray the study's clinical site costs. As described in the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete control over the design of the protocol, ownership of the data, and all editorial content of presentations and publications related to the protocol. A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net.
A published list of the Diabetic Retinopathy Clinical Research Network investigators and staff participating in this protocol can be found in Ophthalmology 2010;117:1064–77.e35 with a current list available at www.drcr.net.